Search
Corvus Pharmaceuticals Inc
CRVSAdd to Watchlist
11.020USD
+0.480+4.55%
Market hours 11/09, 10:35（ET）
927.00MMarket Cap
LossP/E TTM
Corvus Pharmaceuticals Inc (CRVS) Stock Price Target & Forecast
Analyst Rating
Based on 8 analysts giving stock ratings to Corvus Pharmaceuticals Inc in the past month.
Buy
3 Strong Buy
5 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
32.000USD+219.04%
CRVS Analyst Recommendation Trends
In the current month, CRVS has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CRVS average Analyst price target in the last month is 32.000.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
3
3
3
2
2
2
3
3
5
5
5
5
5
5
4
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
8
8
7
7
7
7
7
Financial Forecasting
Based on analysts' estimates, CRVS EPS is projected to reach -0.223 in FY2026Q4, following reported EPS of -0.220 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.14
-0.16
-0.20
-0.22
-0.24
Actual
-0.15
-0.19
-0.22
--
--
Surprise
-6.50%
-22.48%
-9.22%
--
--
FAQs
What is Corvus Pharmaceuticals Inc's price target?
Analysts forecast that Corvus Pharmaceuticals Inc's price target is USD 14.00, with the highest forecast at USD 24.00 and the lowest forecast at USD 11.00.
How have Corvus Pharmaceuticals IncCRVS's recent earnings per share performed?
The market expectation was USD -0.22, while Corvus Pharmaceuticals IncCRVS's earnings per share (EPS) for the previous quarter was USD -0.19. EPS for the next quarter is expected at USD -0.22.
What is the analyst rating for Corvus Pharmaceuticals Inc?
Based on the ratings of Corvus Pharmaceuticals Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.